Literature DB >> 3561662

CSF and serum concentrations of albumin and IgG in Alzheimer's disease.

A D Kay, C May, N M Papadopoulos, R Costello, J R Atack, J S Luxenberg, N R Cutler, S I Rapoport.   

Abstract

Cerebrospinal fluid (CSF) and serum concentrations of albumin and immunoglobulin G (IgG) were measured in 31 patients with presumptive Alzheimer's disease (AD) and in 14 healthy control subjects. The albumin and IgG quotients, and IgG index were calculated to evaluate the permeability of the blood-brain barrier and the intrathecal production of immunoglobulins. X-ray computerized tomography (CT) of the head was performed to investigate the relation between cerebral atrophy and CSF protein concentrations. The albumin and IgG quotients, and the IgG index did not differ significantly between the AD and control groups. Cerebral atrophy, as measured by CSF volume, was not related to CSF protein concentrations in either group. The results do not support the hypothesized roles of blood-brain barrier disruption or of immunologically-mediated injury of the central nervous system in the pathogenesis of AD.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3561662     DOI: 10.1016/0197-4580(87)90053-4

Source DB:  PubMed          Journal:  Neurobiol Aging        ISSN: 0197-4580            Impact factor:   4.673


  15 in total

1.  Alzheimer's disease and the Blood-Brain Barrier: Past, Present and Future.

Authors:  Gene L Bowman; Joseph F Quinn
Journal:  Aging health       Date:  2008-02-01

2.  Serum albumin concentration and cognitive impairment.

Authors:  D J Llewellyn; K M Langa; R P Friedland; I A Lang
Journal:  Curr Alzheimer Res       Date:  2010-02       Impact factor: 3.498

Review 3.  Drug access to the central nervous system in Alzheimer's disease: preclinical and clinical insights.

Authors:  Dharmini C Mehta; Jennifer L Short; Sarah N Hilmer; Joseph A Nicolazzo
Journal:  Pharm Res       Date:  2014-10-16       Impact factor: 4.200

4.  Immunohistochemical localization of intracellular plasma proteins in the human central nervous system.

Authors:  H M Liu; J R Atack; S I Rapoport
Journal:  Acta Neuropathol       Date:  1989       Impact factor: 17.088

5.  Clinical significance of neurobiochemical profiles in the lumbar cerebrospinal fluid of Alzheimer's disease patients.

Authors:  N Rösler; I Wichart; K A Jellinger
Journal:  J Neural Transm (Vienna)       Date:  2001       Impact factor: 3.575

6.  Studying Human Neurological Disorders Using Induced Pluripotent Stem Cells: From 2D Monolayer to 3D Organoid and Blood Brain Barrier Models.

Authors:  Sarah Logan; Thiago Arzua; Scott G Canfield; Emily R Seminary; Samantha L Sison; Allison D Ebert; Xiaowen Bai
Journal:  Compr Physiol       Date:  2019-03-14       Impact factor: 9.090

7.  Dysfunction of the blood-cerebrospinal fluid-barrier and N-methyl-D-aspartate glutamate receptor antibodies in dementias.

Authors:  Mandy Busse; Ralf Kunschmann; Henrik Dobrowolny; Jessica Hoffmann; Bernhard Bogerts; Johann Steiner; Thomas Frodl; Stefan Busse
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2017-02-08       Impact factor: 5.270

8.  Systemic immune system alterations in early stages of Alzheimer's disease.

Authors:  Rongzhen Zhang; Robert G Miller; Catherine Madison; Xia Jin; Ronald Honrada; Will Harris; Jonathan Katz; Dallas A Forshew; Michael S McGrath
Journal:  J Neuroimmunol       Date:  2013-02-04       Impact factor: 3.478

9.  Alzheimer's disease: paired helical filament immunoreactivity in cerebrospinal fluid.

Authors:  G P Wang; K Iqbal; G Bucht; B Winblad; H M Wisniewski; I Grundke-Iqbal
Journal:  Acta Neuropathol       Date:  1991       Impact factor: 17.088

Review 10.  Blood-brain barrier dysfunction as a cause and consequence of Alzheimer's disease.

Authors:  Michelle A Erickson; William A Banks
Journal:  J Cereb Blood Flow Metab       Date:  2013-08-07       Impact factor: 6.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.